Ghrelin-Induced Orexigenic Effect in Rats Depends on the Metabolic Status and Is Counteracted by Peripheral CB1 Receptor Antagonism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Alen, Francisco ^a   Crespo, Inmaculada ^a   Ramírez López, María Teresa ^a   Jagerovic, Nadine ^b   Goya, Pilar ^b   de Fonseca, Fernando Rodríguez ^a,c,d   de Heras, Raquel Gómez ^a   Orio, Laura ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; GHRELIN; LH 21; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; APPETITE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; ENERGY BALANCE; FOOD DEPRIVATION; FOOD INTAKE; HYPERPHAGIA; IN VIVO STUDY; MALE; METABOLIC PARAMETERS; METABOLIC STATUS; NONHUMAN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; EATING; GHRELIN; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; TRIAZOLES;

ANIMALIA; RATTUS;

EID: 84875679175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060918     Document Type: Article

References (64)

1. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, et al. (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 86: 4753-4758.
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
3. Sakata I, Nakamura K, Yamazaki M, Matsubara M, Hayashi Y, et al. (2002) Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 23: 531-536.
4. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, et al. (2001) Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 50: 2438-43.
5. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-8.
6. Popovic V, Miljic D, Micic D, Damjanovic S, Arvat E, et al. (2003) Ghrelin main action on the regulation of growth hormone release is exerted at hypothalamic level. J Clin Endocrinol Metab 88: 3450-3453.
7. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ, (2006) Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol. 290: G1289-97.
8. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, et al. (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48: 23-29.
9. Bermudez-Silva FJ, Cardinal P, Cota D, (2012) The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol. 26: 114-24.
10. Di Marzo V, Matias I, (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8: 585-589.
11. Piomelli D, (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
12. Viveros Mp, de Fonseca FR, Bermudez-Silva FJ, McPartland JM, (2008) Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets. 8: 220-30.
13. Crespo I, Gomez de Heras R, Rodriguez de Fonseca F, Navarro M, (2008) Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1. Neuropharmacology 54: 219-225.
14. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G, (2006) Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and-independent coordinated alterations of receptor localization and function. J Biol Chem 281: 38812-38824.
15. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P, (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278: 23731-23737.
16. Orio L, Crespo I, Lopez-Moreno JA, Reyes-Cabello C, Rodriguez de Fonseca F, et al. (2011) Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. Pharmacol Biochem Behav. 98: 220-6.
17. Verty AN, McFarlane JR, McGregor IS, Mallet PE, (2004) Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 47: 593-603.
18. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
19. Matias I, Vergoni AV, Petrosino S, Ottani A, Pocai A, et al. (2008) Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 54: 206-212.
20. Verty AN, McFarlane JR, McGregor IS, Mallet PE, (2004) Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145: 3224-3231.
21. Kirkham TC, Williams CM, (2001) Synergistic efects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 153: 267-270.
22. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, et al. (2001) Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344-5350.
23. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, et al. (2008) The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 3: 797.
24. Tucci SA, Rogers EK, Korbonits M, Kirkham TC, (2004) The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143: 520-523.
25. Cota D, (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev. 23: 507-17.
26. Di M, Despres JP, (2009) CB1 antagonists for obesity--what lessons have we learned from rimonabant? Nat Rev Endocrinol 5(11): 633-8.
27. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.
28. Moreira F, Crippa JA, (2009) The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr. 31: 145-53.
29. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F, (2010) The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 95: 375-382.
30. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, et al. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8: 491-6.
31. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, et al. (2008) Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 51: 476-87.
32. Hornby PJ, Prouty SM, (2004) Involvement of cannabinoid receptors in gut motility and visceral perception. 141: 1335-45.
33. Kunos G, Tam J, (2011) The case for peripheral CB receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 163: 1423-31.
34. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R, (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 27: 73-100.
35. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, et al. (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 9612-9617.
36. Pavon FJ, Bilbao A, Hernandez-Folgado L, Cippitelli A, Jagerovic N, et al. (2006) Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. Neuropharmacology 51: 358-366.
37. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, et al. (2008) Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol. 20Suppl 1: 116-23.
38. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordenates. IV Edition. Academic Press.
39. Hernandez-Folgado L, Schmuck C, Tomic S, Piantanida I, (2008) A novel pyrene-guanidiniocarbonyl-pyrrole cation efficiently differentiates between ds-DNA and ds-RNA by two independent, sensitive spectroscopic methods. Bioorg Med Chem Lett 18: 2977-81.
40. Cummings DE, Frayo RS, Marmonier C, Aubert R, Chapelot D, (2004) Plasma ghrelin levels and hunger scores in humans initiating meals voluntarily without time- and food-related cues. Am J Physiol Endocrinol Metab 287: E297-304.
41. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, et al. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50: 1714-1719.
42. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, et al. (2001) Upregulation of Ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 281: 1220-1225.
43. Tschop M, Wawarta R, Riepl RL, Friedrich S, Bidlingmaier M, et al. (2001) Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 24: RC19-21.
44. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, et al. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 87: 240-4.
45. Rodriguez A, Gomez-Ambrosi J, Catalan V, Gil MJ, Becerril S, et al. (2009) Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 33: 541-52.
46. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, et al. (2000) Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. Cholecystokinin. J Neurosci. 24: 2708-15.
47. Alonso M, Serrano A, Vida M, Crespillo A, Hernandez-Folgado L, et al. (2012) Antiobesity Efficacy Of LH-21, A Cannabinoid CB(1) Receptor Antagonist With Poor Brain Penetration, In Diet-Induced Obese Rats. Br J Pharmacol 165: 2274-91.
48. Al-Massadi O, Gabellieri E, Trujillo ML, Senaris R, Pagotto U, et al. (2010) Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent. J Neuroendocrinol 22: 1127-36.
49. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM, (2004) Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 92: 757-761.
50. Date Y, Toshinai K, Koda S, Miyazato M, Shimbara T, et al. (2005) Peripheral interaction of ghrelin with cholecystokinin on feeding regulation. Endocrinology 146: 3518-25.
51. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, et al. (2001) Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120: 337-45.
52. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, et al. (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120-8.
53. Madsen A, Jelsing J, van de Wall E, Vrang N, Larsen PJ, et al. (2009) Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. Neurosci Lett. 449: 20-3.
54. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, et al. (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280: 25196-25201.
55. van Thuijl H, Kola B, Korbonits M, (2008) Appetite and metabolic effects of ghrelin and cannabinoids: involvement of AMP-activated protein kinase. Vitam Horm 77: 121-148.
56. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, et al. (2008) mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 108: 308-319.
57. Przybyla JA, Watts VJ, (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332: 710-719.
58. Ward RJ, Pediani JD, Milligan G, (2011) Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A. J Biol Chem 286: 37414-37428.
59. Schellekens H, van Oeffelen WE, Dinan TG, Cryan JF, (2013) Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. J Biol Chem 288: 181-191.
60. Mackie K, (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 168: 299-325.
61. Sim LJ, Selley DE, Childers SR, (1995) In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc Natl Acad Sci U S A 92: 7242-7246.
62. Mondal MS, Date Y, Yamaguchi H, Toshinai K, Tsuruta T, et al. (2005) Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul Pept. 126: 55-9.
63. Merchenthaler I, (1991) Neurons with access to the general circulation in the central nervous system of the rat: a retrograde tracing study with fluoro-gold. Neuroscience 44: 655-662.
64. Breivogel CS, Childers SR, (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5: 417-431.